FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
for Metastatic Head and Neck Squamous Cell Carcinoma
Sites in Los Angeles, San Francisco +48 more locations
Sponsor: Bicara Therapeutics
Sex: All·Age: 18+
Code: NCT06788990·Phase 2, Phase 3·Recruiting·Listed Jan 2025